伊布替尼、奥妥珠单抗与维奈克拉联合治疗复发及初治套细胞淋巴瘤的1/2期试验
OAsIs单臂多中心前瞻性1/2期试验评估伊布替尼、奥妥珠单抗固定剂量联合维奈克拉在复发及初治套细胞淋巴瘤患者中的耐受性和疗效,共入组48例,未报告剂量限制性毒性,维奈克拉扩展期剂量选为400 mg/日,复发和初治患者均获得高完全缓解率和分子学缓解。
要点
- 维奈克拉联合伊布替尼和奥妥珠单抗耐受良好,未报告剂量限制性毒性。
- 6周期末PET评估完全缓解率复发患者67%、初治患者86.6%。
- 可评估患者3周期末MRD清除率复发71.5%、初治100%。
核心结论
- 奥妥珠单抗、伊布替尼与维奈克拉联合方案耐受良好,在复发和初治套细胞淋巴瘤患者中提供高缓解率,包括分子水平缓解。
研究设计与样本
- OAsIs(NCT02558816)为单臂多中心前瞻性1/2期试验,2015年10月14日至2018年5月29日共入组48例患者。
- 主要目的为确定维奈克拉联合固定剂量伊布替尼和奥妥珠单抗在复发套细胞淋巴瘤患者中的最大耐受剂量。
- 在维奈克拉最大耐受剂量下开设复发和初治患者扩展队列,安全性和疗效为次要目标。
主要发现
- 未报告剂量限制性毒性,扩展期维奈克拉剂量选为400 mg/日。
- 18例(75%)复发患者和8例(53%)初治患者发生3/4级不良事件。
- 6周期末PET评估完全缓解率复发患者67%、初治患者86.6%。
- 可评估患者3周期末MRD清除率复发71.5%(10/14例)、初治100%(n=12)。
- 复发患者中位随访17个月(范围10-35个月),2年无进展生存率69.5%(95%CI 52.9%-91.4%),总生存率68.6%(95%CI 49.5%-95.1%);初治患者中位随访14个月(范围5-19个月),1年无进展生存率93.3%(95%CI 81.5%-100%)。
临床怎么用
- 该联合方案可用于复发和初治套细胞淋巴瘤患者,需关注3/4级不良事件。
- 治疗中可通过MRD监测评估分子学缓解深度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was reported, and venetoclax at 400 mg per day was chosen for extension. Eighteen (75%) relapsed and 8 (53%) untreated patients experienced grade 3/4 adverse events. The complete response rate assessed by positron emission tomography at the end of cycle 6 was 67% in relapsed and 86.6% in untreated patients. MRD clearance for evaluable patients was seen in 71.5% of relapsed (10/14 patients) and 100% of untreated MRD-evaluable patients (n = 12) at the end of 3 cycles. The median follow-up for relapsed patients was 17 months (range, 10-35 months). The 2-year progression-free survival (PFS) was 69.5% (95% confidence interval [CI], 52.9%-91.4%) and 68.6% (95% CI, 49.5%-95.1%) for overall survival. The median follow-up was 14 months (range, 5-19) for untreated patients, the 1-year PFS was 93.3% (95% CI, 81.5%-100%). The combination of obinutuzumab, ibrutinib, and venetoclax is well tolerated and provides high response rates, including at the molecular level, in relapsed and untreated MCL patients. This trial was registered at www.clinicaltrials.gov as #NCT02558816.
引用
- Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021. PMID: 33181832. doi:10.1182/blood.2020008727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。